US 12629391 B1Patent grantUnited States

Cobalt Nanocomposite for Cancer-Cell Screening

Official patent title

Method of treating cancer cells using cobalt oxide/calcium silicate@graphitic carbon nitride (CoO/CaSiO3@g-C3N4) nanocomposite

Arabic title: طريقة لعلاج الخلايا السرطانية باستخدام المركب النانوي من أكسيد الكوبالت/سيليكات الكالسيوم@نتريد الكربون الغرافيتي (CoO/CaSiO3@g-C3N4)

Invention

Problem

Cancer treatment resistance and nonspecific toxicity motivate new cell-active material screens, but apparent cancer-cell inhibition must be separated from general cobalt-related cytotoxicity.

Why it matters

In-vitro cell-line results can support early hypothesis generation, but they do not demonstrate tumor selectivity, safe systemic exposure, animal efficacy, patient benefit, or clinical treatment value.

Approach

The method contacts MCF-7 breast-carcinoma or HepG-2 hepatocellular-carcinoma cells with a CoO/CaSiO3@g-C3N4 composite and measures inhibition in an in-vitro viability assay.

Who may benefit

Potential beneficiaries include preclinical oncology researchers, nanotoxicology laboratories, cobalt-material chemists, cell-assay developers, and early-stage cancer-discovery teams.

Potential value

The disclosure connects a characterized cobalt-silicate-carbon-nitride material with patent-stated viability inhibition in two cancer cell lines and defined particle and pore properties.

Background

Nanomaterials are studied as drug carriers and as cell-active agents, but an observed reduction in cultured cancer-cell viability can reflect nonspecific toxicity rather than selective anticancer action. Translation requires reproducible concentration-response testing, comparison with normal cells, mechanism, uptake, and release characterization before animal work. The publication reports in-vitro results in MCF-7 and HepG-2 lines for a cobalt-containing composite. It does not provide normal-cell selectivity, exposure concentration in the supplied claims, IC50 values, cell-death mechanism, cobalt-release data, genotoxicity, hemocompatibility, pharmacokinetics, animal efficacy, formulation, or clinical evidence.

Technology overview

CoO and CaSiO3 particles are dispersed on g-C3N4 nanosheets. Their stated diameter is 340–440 nm, with narrower ranges of 370–410 nm and 380–400 nm. Patent-stated in-vitro inhibition is at least 55% for MCF-7 and at least 60% for HepG-2, with stated values of 77% and 76%, respectively. BET area is at least 20 m2·g−1 and reaches at least 30 m2·g−1; pore volume reaches at least 0.195 cm3·g−1, and average pore diameter is 21.82 nm.

Potential applications

Early preclinical cancer-cell viability screening.
Comparative MCF-7 and HepG-2 material-response studies.
Cobalt-release and nanotoxicology research.
Nanocomposite structure-cell interaction studies.

Evidence-supported advantages

Two human cancer cell lines are addressed in vitro.
Patent-stated inhibition values are supplied for both lines.
Particle, surface-area, pore-volume, and pore-diameter values are defined.
XRD, TEM, diffraction, and sorption characterization are described.

Development stage

Laboratory material characterization and in-vitro viability testing in MCF-7 and HepG-2 cells are described; dose-response detail, normal-cell selectivity, mechanism, animal studies, pharmacology, and clinical validation were not established.

Commercial opportunity

This is early in-vitro evidence, not an established cancer therapy. Development requires independent dose-response replication, normal-cell selectivity, cobalt dissolution and mechanism studies, genotoxicity, immune and blood compatibility, exposure and biodistribution, formulation, animal efficacy and toxicology, manufacturing controls, and regulatory clinical trials. The reported percentages cannot predict patient benefit or safety.

Patent classifications

WIPO IPC

A61K33/24Preparations for medical, dental or toiletry purposes
A61K9/16Preparations for medical, dental or toiletry purposes

CPC

A61K33/24Preparations for medical, dental or toiletry purposes
A61K9/16Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
A61K9/5115Preparations for medical, dental or toiletry purposes

Inventors

First inventorMohamed Khairy Abdel Fattah Omran
InventorBabiker Yagoub Elhadi Abdulkhair

Keywords

cobalt oxide
calcium silicate
graphitic carbon nitride
MCF-7
HepG-2
cell viability
in-vitro inhibition
nanotoxicology

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.